Recent developments include Q2 2026 earnings results highlighting sales growth and margin improvement, workforce restructuring initiatives, and strategic acquisitions to expand product offerings.

• Boston Scientific reported Q2 2026 earnings with net sales growth driven by Endoscopy, Neuromodulation, and Cardiovascular segments, though Urology showed flat growth due to challenges in China and sacral neuromodulation [N2][N3][N4][N5][N6].
• Gross profit margin improved to 70.7% in Q2 2026, supported by higher sales of premium products and tariff recoveries [N2][N3].
• SG&A expenses increased by 5% in Q2 2026 but decreased as a percentage of sales, reflecting operational efficiency [N2][N3].
• R&D expenses increased by 5% in Q2 2026, supporting ongoing product development and pipeline maintenance [N2][N3].
• The company is executing a global restructuring program initiated in 2023, expanded in 2025, with activities substantially complete by end of 2025; a new restructuring program was approved in July 2026 [N1].
• Liquidity remains solid with $539 million in cash and cash equivalents as of June 30, 2026, supported by new revolving credit agreements entered in February 2026 [N1].
• Recent workforce reductions and restructuring efforts aim to optimize manufacturing and distribution networks [N1].

Boston Scientific's broad and innovative product portfolio across multiple high-growth medical device segments provides opportunities for sustained sales growth. The company's focus on less-invasive technologies and expansion in Emerging Markets supports market penetration. Continued investments in R&D and strategic acquisitions may enhance its pipeline and competitive positioning. Operational restructuring initiatives could improve efficiency and profitability. The company's solid liquidity and access to capital markets support ongoing investments and potential acquisitions.

Boston Scientific faces competitive pressures in key segments such as Electrophysiology, with noted deceleration in certain procedures like WATCHMAN. The discontinuation of certain product lines, such as the ACURATE Aortic Valve Systems, reflects challenges in product development and market acceptance. Restructuring charges and legal-related liabilities may impact financial performance. Regulatory changes, including EU MDR implementation and evolving tax legislation, introduce compliance risks. Market dynamics in Emerging Markets, including volume-based procurement policies, may constrain growth in some franchises. Execution risks in integrating acquisitions and maintaining innovation pace also exist.

Boston Scientific's moat is supported by its diversified portfolio of innovative medical devices across multiple therapeutic areas, including proprietary technologies such as the Farapulse Pulsed Field Ablation System and WATCHMAN devices. The company's investments in research and development foster product innovation and clinical evidence generation, which are critical in the highly regulated medical device industry. Its global commercial presence, including expansion in Emerging Markets, and strategic acquisitions enhance market penetration and product breadth. The company's restructuring efforts aim to optimize manufacturing and distribution, potentially improving cost efficiency and competitive positioning. However, the medical device industry is competitive and subject to regulatory and reimbursement challenges, requiring continuous innovation and execution.

• Competitive Pressure: Increased competition in key business units, such as Electrophysiology, and deceleration in certain procedures like WATCHMAN may impact sales growth.
• Product Discontinuation: Discontinuation of ACURATE Aortic Valve Systems and cessation of FDA approval pursuit indicate challenges in product portfolio management.
• Restructuring and Related Charges: Ongoing restructuring programs involve significant pre-tax charges and operational changes that may affect financial results and employee morale.
• Regulatory and Compliance Risks: Implementation of EU MDR, evolving tax laws including the One Big Beautiful Bill Act and OECD Pillar Two framework, and litigation exposures pose compliance and financial risks.
• Market and Geopolitical Risks: Emerging Markets growth may be affected by volume-based procurement policies and commercial disruptions, particularly in China.

• Boston Scientific operates in the Healthcare sector within the Medical Devices industry.
• The company develops and manufactures medical devices across several business segments: Endoscopy, Urology, Neuromodulation, MedSurg, and Cardiovascular.
• Endoscopy segment focuses on devices for gastrointestinal conditions using less-invasive technologies, with key products including AXIOS Stent and Delivery System and EXALT Model D Single-Use Duodenoscope.
• Urology segment addresses conditions such as kidney stones, BPH, prostate cancer, erectile dysfunction, and incontinence; key franchises include stone management and sacral neuromodulation, with products like Lumenis Pulse Holmium Laser Systems and Rezūm Systems.
• Neuromodulation segment develops devices for neurological movement disorders and chronic pain, including Intracept Intraosseous Nerve Ablation System, Nalu Peripheral Nerve Stimulation System, spinal cord stimulation, and deep brain stimulation franchises.
• Cardiovascular segment includes devices for heart diseases, peripheral arterial and venous diseases, and cancer treatments; notable products include Farapulse Pulsed Field Ablation (PFA) System, WATCHMAN Left Atrial Appendage Closure Devices, and AGENT Drug-Coated Balloon.
• The company discontinued worldwide sales of ACURATE Neo2 and ACURATE Prime Aortic Valve Systems and ceased pursuing FDA approval for these products, reallocating resources to other portfolio areas.
• Boston Scientific has a strategic focus on global expansion, particularly in Emerging Markets such as China, driven by portfolio breadth and innovation.
• Reported net sales for the six months ended June 30, 2026, were $10.646 billion, representing a 9.5% increase on a reported basis and 8.1% on an organic basis compared to the prior year period.
• Segment net sales growth for the six months ended June 30, 2026, included Endoscopy (6.9% organic), Urology (0.6% organic), Neuromodulation (13.7% organic), MedSurg (5.6% organic), and Cardiovascular (9.4% organic).
• Gross profit for Q2 2026 was $3.848 billion with a gross margin of 70.7%, up from 67.7% in Q2 2025, driven by higher sales of higher margin products, tariff recoveries, and reduced inventory charges.
• Selling, General and Administrative (SG&A) expenses increased by 5% in Q2 2026 compared to Q2 2025 but decreased as a percentage of net sales to 33.1%.
• Research and Development (R&D) expenses increased by 5% in Q2 2026 compared to Q2 2025 but decreased slightly as a percentage of net sales to 10.2%.
• The company has been executing a global restructuring program initiated in 2023, expanded in 2025, with total pre-tax charges estimated between $700 million and $800 million; activities were substantially complete by end of 2025.
• A new global restructuring program was approved and committed to by the Board on July 21, 2026.
• As of June 30, 2026, Boston Scientific held $539 million in unrestricted cash and cash equivalents, with a current ratio of 1.24 and a cash ratio of 0.08, indicating liquidity to support operations and investments.
• The company entered into new revolving credit agreements in February 2026, including a $3 billion revolving credit agreement maturing in 2031, and additional credit facilities related to a pending acquisition of Penumbra, Inc.
• Cash flow from operating activities for the six months ended June 30, 2026, was $1.822 billion, relatively flat compared to the prior year period.
• Investing activities included $718 million in acquisitions primarily related to Nalu Medical, Inc., and $1.501 billion in investments including MiRus LLC, with $372 million spent on property, plant, equipment, and software.
• Financing activities included issuance of commercial paper, share repurchases totaling $2 billion, and repayment of senior notes.
• Reported tax rate for Q2 2026 was 14.6%, with a rate from continuing operations of 17.3%, influenced by discrete tax benefits and return-to-provision adjustments.
• The company faces competition in its Electrophysiology business unit and has experienced a deceleration in certain WATCHMAN procedures.
• The company invests in R&D to maintain a pipeline of products contributing to sales growth and supports development and clinical evidence for newly acquired technologies.
• The company manages risks related to litigation, restructuring, and regulatory compliance, including EU MDR implementation costs and tax legislation changes such as the One Big Beautiful Bill Act and OECD Pillar Two framework.